Helius Medical Technologies (Nasdaq:HSDT) announced today that it established Revelation Neuro, a brain-computer interface (BCI) subsidiary.
The wholly-owned private subsidiary focuses on the development of non-implantable, AI-powered BCI technology. It aims to produce a unique, less invasive option.
“We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of care for personalized neurorehabilitation using a non-implantable AI powered BCI combining our newly developed IP with Helius’ existing IP,” said Dane Andreeff, Helius president and CEO. “Our technology relies on its proven ability to modulate known target brain processes and trigger therapeutic responses by using translingual stimulation without risky implantation.”
Helius Medical develops its own portable neuromodulation stimulator platform. It intends to assign its newly developed IP and license existing IP to Revelation Neuro. Helius has an extensive dataset from more than five years of movement dysfunction clinical evidence from more than 400 subjects. The subsidiary plans to use that as a foundation for AI algorithm development, eventually adding more data for optimization. This can enable a precise, personalized approach to motor function rehabilitation.
The company said it has more than $70 million invested to date. It develops a novel and proprietary neuromodulation mechanism of action. It believes data gathering can allow expedited development of the AI-powered BCI. (Read more about recent updates in the BCI space here).
Helius does not intend to invest significant additional capital in Revelation Neuro. It expects financing through third-party outside sources.
“Revelation Neuro is focused on maximizing the positive effect of neuromodulation by applying AI to optimize individual response to translingual stimulation. Revolutionary BCI-enabled improvement in functional rehabilitation is the initial focus of Revelation Neuro’s efforts, with the potential in the future to address neurological conditions including cognitive deficit, mood and behavior disorders,” Andreeff said.
